Skip to main content

. 1980 Jul 26;281(6235):275–276. doi: 10.1136/bmj.281.6235.275-a

Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.

I N Olver, G L Jennings, A Bobik, M Esler

PMCID: PMC1713839 PMID: 7427244

275

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Aellig W. H., Nüesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm. 1977 Mar;15(3):106–112. [PubMed] [Google Scholar]
Jennings G., Esler M., Holmes R. Treatment of orthostatic hypotension with dihydroergotamine. Br Med J. 1979 Aug 4;2(6185):307–307. doi: 10.1136/bmj.2.6185.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rosenthaler J., Munzer H. 9-10-dihydroergotamine: production of antibodies and radioimmunoassay. Experientia. 1976 Feb 15;32(2):234–236. doi: 10.1007/BF01937784. [DOI] [PubMed] [Google Scholar]
Ziegler M. G., Lake C. R., Kopin I. J. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med. 1977 Feb 10;296(6):293–297. doi: 10.1056/NEJM197702102960601. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES